Results 131 to 140 of about 113,185 (266)

Navigating the Complexity: A Comprehensive Review of GSK‐3 Inhibition in Regenerative Medicine

Medicinal Research Reviews, EarlyView.
ABSTRACT Glycogen synthase kinase‐3 (GSK‐3) is a central regulator of numerous cellular signaling pathways, with critical roles in metabolism, proliferation, differentiation, and tissue regeneration. This review explores the multifaceted effects of pharmacological GSK‐3 inhibition across multiple body districts, focusing on its highly context‐dependent
Davide Schiroli, Alessia Merra, Chiara Marraccini, Lucia Merolle, Graziella Pellegrini, Eleonora Maurizi   +5 more
wiley   +1 more source

Roth Spots As the Initial Manifestation of Accelerated-Phase Chronic Myeloid Leukemia. [PDF]

Cureus
Benchekroun M, Hamidi S, Fakhir B, Benchekroun Belabbas S, Cherkaoui LO.   +4 more
europepmc   +1 more source

Exploring the Value of Quantitative Muscle Ultrasound in Neuromuscular Junction Disorders: A Pilot Study

Muscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims Quantitative muscle ultrasound (QMUS) is a validated technique for assessing muscle pathology, yet its role in disorders primarily affecting the neuromuscular junction (NMJ) remains unclear. This pilot study aimed to explore whether QMUS is associated with structural muscle changes in patients with acquired or genetic NMJ ...
Artor Pogosean, Maarika Liik, Nens van Alfen, Anna Rostedt Punga   +3 more
wiley   +1 more source

Real-life data of patients with chronic myeloid leukemia in Amazonas. [PDF]

BMC Cancer
Abreu RS, Maior KS, Souza IML, Paes JF, Nascimento BEF, Santos RO, Romero NPG, Martins JP, Costa AG, Malheiro A, Martins-Filho OA, Tarragô AM, Passos LNM.   +12 more
europepmc   +1 more source

Information Design for Early‐Stage Dose‐Finding Trials

Naval Research Logistics (NRL), EarlyView.
ABSTRACT To enhance enrollment rates in early‐stage dose‐finding clinical trials, we propose an information design approach, where the clinical investigator (CI) commits to an information releasing mechanism (IRM) based on the treatment's uncertain efficacy and toxicity to encourage patients to participate in the trial.
Amin Khademi, Ningyuan Chen
wiley   +1 more source

Development of Colonic Polyposis in a Woman With Chronic Myeloid Leukemia Treated With Dasatinib. [PDF]

Case Rep Hematol
Pelaez G, Yildiz BS, Candan M, Ismail M, Vacca F, Ruzinova MB, Ballentine S, Byrnes K, Ghobadi A.   +8 more
europepmc   +1 more source

Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of ‘‐mabs’?

The Journal of Pathology, EarlyView.
Abstract Prostate cancer (PCa) is the second most common type of neoplasm, currently treated with a variety of therapeutic agents. Although advances in treatment over the past decade have improved overall survival, patients with advanced PCa eventually progress from hormone‐sensitive PCa to metastatic castration‐resistant PCa.
Giuseppe Schepisi, Irene Torresan, Emilio Francesco Giunta, Sara Bleve, Nicole Brighi, Elisa Tassinari, Sofia Zanuccoli, Maria Concetta Cursano, Cristian Lolli   +8 more
wiley   +1 more source

A Current Overview of Quality-of-Life Research in Chronic Myeloid Leukemia (CML). [PDF]

Cancers (Basel)
Deneberg S.
europepmc   +1 more source

The Transformative Journey of Chronic Myeloid Leukemia [PDF]

International Journal of Hematologic Oncology, 2018
Neelakantan, Pratap, Mead, Adam
openaire   +2 more sources

In Utero HSC Transplantation for Sickle Cell Disease: A Potential Therapeutic Approach That Overcomes Complications of Current Therapies

Prenatal Diagnosis, EarlyView.
ABSTRACT Sickle cell disease (SCD) affects millions worldwide but has limited treatment options, most of which carry significant side effects. At present, the only curative treatment for SCD is allogeneic or gene‐modified autologous hematopoietic stem cell (HSC) transplantation (Tx).
Oluwaseun O. Babatunde, Madeleine G. Bibby, Anthony Atala, Graça Almeida‐Porada, Christopher D. Porada   +4 more
wiley   +1 more source